Professor Rob Coleman MBBS, MD, FRCP, FRCPE
Professor of Medical Oncology, University of Sheffield; Head of Academic Unit of Clinical Oncology
Department of Oncology & Metabolism
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Office: Broomcross Building, Floor 2
Tel: +44 (0)114 226 5213
Fax: +44 (0)114 226 5364
Professor Robert (Rob) Coleman graduated from Kings College Hospital Medical School, University of Londong in 1978. Following clinical training in oncology in London and Edinburgh and completion of a research doctorate (MD) in the field of bone metastases, he became senior lecturer and honorary consultant in the newly formed Academic Unit of Clinical Oncology at Weston Park Hospital in 1991 and was subsequently promoted to Reader in 1996 and Professor in 1999. For more than 25 years he has been instrumental in developing clinical cancer research in the city and surrounding clinical network and is passionate about improving the care of cancer patients through research. During that time he has held many leadership roles within the university and the NIHR Cancer Research Network. Since 2014 he has been a part-time Medical Director for the independent medical education provider, prIME Oncology™ alongside his on-going, but now part-time clinical academic role within the university.
Rob established a highly successful cancer clinical trials facility, which has both led and participated in a broad range of clinical trials and provides the research infrastructure for the North Trent Cancer Research Network and the Experimental Cancer Medicine Centre. These trials have ranged from early phase drug development studies to large phase III randomised trials. Since the mid 1980s, Rob’s main research interest has been into cancer induced bone disease with a particular focus in breast cancer. His research in this area is wide ranging and internationally recognised and includes:
- clinical aspects of care
- the development of bone targeted agents in oncology
- use of bone targeted treatments to prevent metastasis
- evaluation of bone biomarkers in oncology to aid drug development and provide both prognostic and predictive information of clinical value
- the assessment of adverse effects of cancer treatments on bone health and evaluation of various treatment strategies.
Rob has authored or co-authored 400 publications of original research and numerous invited reviews and book chapters. He is the founding editor of Journal of Bone Oncology, on the editorial board of several oncology journals and a reviewer for numerous journals. He is also a Trustee for Breast Cancer Now, St Luke’s Hospice and Weston Park Hospital Cancer Charity.
Current active grants
- Breast Cancer Campaign. Potential biomarkers of bone metastasis - functional studies and clinical significance (Co-Appl) - £183,487– 2014-2016
- Cancer Research UK: Experimental Cancer Medicine Centre (Co-Appl) - £1,000,000 – 2012-2017
- Cancer Research UK: Testosterone Replacement in Young Male Survivors of Cancer (TRYMS) (Co-Appl): £500,075 - 2010 - 2015
- Health technology Assessment - HTA Project: 12/35/17 - POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes. (Co-Appl) £2,100,000– 2014-2023
- Medical Research Council/AstraZeneca. Mechanisms of Disease. The role of Src in cancer-induced bone pain. (Co-Appl):- £884,626 – 2013-2016.
- National Institute for Health Research. Bridging the age gap in breast cancer. Improving outcomes for older women (Co-Appl) £1,705,273 – 2013-2018
- Novartis Pharmaceuticals (AZURE Clinical Trial) (PI): - £5,517,737 - 2003-2016
- Novartis Pharmaceuticals (AZURE BMD Sub-study) (PI): - £456,512 - 2009-2016
- Yorkshire Cancer Research. The Yorkshire Cancer Research Early Clinical Trials Network (Co-Appl):- £750,000 2014-2018
- Yorkshire Cancer Research: Menopausal status modifies breast cancer progression and response to therapy – Clinical Fellowship (Co-Appl) - £180,000 - 2015-2018
- Bayer Pharmaceuticals A randomised phase IB/IIA study of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) - Clinical Trial Grant (PI) - £314,486 – 2016-2019
1. Coleman RE., Marshall H., Cameron D., Dodwell D., Burkinshaw R., Keane M., Gil M., Houston SJ., Grieve RJ., Barrett-Lee PJ., Ritchie D., Pugh J., Gaunt C., Rea U., Peterson J., Davies C., Hiley V., Gregory W., Bell R on behalf of the AZURE investigators. Breast Cancer Adjuvant Therapy with Zoledronic Acid. N Engl J Med, 365: 1396-1405, 2011.
2. Smith MR., Saad F., Coleman R., Shore N., Fizazi K., Tombal B., Miller K., Sieber P., Karsh L., Damiao R., Tammela TL., Egerdie B., Van Poppel H., Chin J., Morote J., Gomez-Veiga F., Borkowski T., Ye Z., Kupic A., Dansey R., Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet 379: 39-46, 2012.
3. Coleman R., De Boer R., Eidtmann H., Llombart A., Davidson N., Neven P., von Minckwitz G., Sleeboom H, Forbes J., Barrios C., Frassoldati A., Campbell I, Paija O., Martin N., Modi A., Bundred N. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology 24(2): 398-405, 2013.
4. Winter MC., Wilson C., Syddall SP., Cross SS., Evans A., Ingram CE., Jolley IJ., Hatton MQ., Freeman JV., Mori S., Holen I., Coleman RE. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer – a randomised biomarker pilot study. Clinical Cancer Research 19(10):2755-65, 2013
5. Rathbone EJ., Brown JE., Marshall HC., Collinson M., Liversedge V., Murden GA., Cameron D., Bell R., Spensley S., Agrawal R., Jyothirmayi R., Chakraborti P., Yuille F., Coleman RE. Osteonecrosis of the Jaw and Oral Health – Related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG1/04). Journal of Clinical Oncology 31/21:2685-2692, 2013.
6. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 18;369:213-23, 2013
7. Barrett-Lee P., Casbard A., Abraham J., Hood K., Coleman R., Simmonds P., Timmins H., Wheatley D., Grieve R., Griffiths G., Murray N. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncology 15(1):114-22, 2014.
8. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncology 15(7):738-46, 2014.
9. Coleman RE, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H, on behalf of the AZURE investigators .Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncology 2014, 15(9):997-1006.
10. Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes, JF Howell A, Eastell R. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial Lancet Oncology 15(13)1460-1468, 2014.
11. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson N, Geyer CE Jr., Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, for the SOFT Investigators and the International Breast Cancer Study Group. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Eng J Med 372:436-446, 2015.
12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)* (Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard K, Bliss J, Cameron D, Evans V, Hongchao Pan, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet 386(10001):1353-61, 2015.
13. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. J Natl Cancer Inst. 15;107(12), 2016.
14. P Hadji*, RE Coleman*, C Wilson, T J Powles, P Clézardin, M Aapro, L Costa, J-J Body, C Markopoulos, D Santini, I Diel, A Di Leo, D Cameron, D Dodwell, I Smith, M Gnant, R Gray, N Harbeck, B Thurlimann, M Untch, J Cortes, M Martin, U-S Albert, P-F Conte, B Ejlertsen, J Bergh, M Kaufmann, I Holen. (*joint first authors) Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. Annals of Oncology in press 2016
15. Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell P, Banks RE, Selby PJ, Coleman RE, Brown JE. CAPG and GIPC1: Breast cancer biomarkers for bone metastasis development and treatment. J Natl Cancer Inst 2016, Vol. 108, No. 4